WO2018203737A3 - 단백질 반감기를 증가시키는 방법 - Google Patents

단백질 반감기를 증가시키는 방법 Download PDF

Info

Publication number
WO2018203737A3
WO2018203737A3 PCT/KR2018/005239 KR2018005239W WO2018203737A3 WO 2018203737 A3 WO2018203737 A3 WO 2018203737A3 KR 2018005239 W KR2018005239 W KR 2018005239W WO 2018203737 A3 WO2018203737 A3 WO 2018203737A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
life
present
fsh
lysine residues
Prior art date
Application number
PCT/KR2018/005239
Other languages
English (en)
French (fr)
Other versions
WO2018203737A2 (ko
Inventor
백광현
김경곤
김명선
김현미
오수경
이미정
배성렬
Original Assignee
주식회사 유비프로틴
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 유비프로틴 filed Critical 주식회사 유비프로틴
Priority to US16/611,089 priority Critical patent/US20200270301A1/en
Priority to JP2019560669A priority patent/JP2020518270A/ja
Priority to CN201880042102.6A priority patent/CN110785429A/zh
Priority to EP18794624.9A priority patent/EP3628681A4/en
Publication of WO2018203737A2 publication Critical patent/WO2018203737A2/ko
Publication of WO2018203737A3 publication Critical patent/WO2018203737A3/ko
Priority to JP2022138031A priority patent/JP2022169770A/ja
Priority to JP2022138032A priority patent/JP2022169771A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)

Abstract

본 발명은 단백질의 아미노산 서열에 존재하는 하나 이상의 라이신 잔기를 치환하는 것을 포함하여 단백질의 반감기를 증가시키는 방법 또는 반감기가 증가 된 단백질에 관한 것으로서, 본 발명의 라이신 잔기가 치환된 단백질은 인체 내에서 오랜 시간 동안 잔류하며 치료효과가 우수하다. 본 발명의 단백질은 EGF, PDGFA 및 PDGFB, GM-CSF, FSH-alpha 및 FSH-beta, 및 ANGPT-1 이다.
PCT/KR2018/005239 2017-05-05 2018-05-05 단백질 반감기를 증가시키는 방법 WO2018203737A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US16/611,089 US20200270301A1 (en) 2017-05-05 2018-05-05 Method for extending half-life of protein
JP2019560669A JP2020518270A (ja) 2017-05-05 2018-05-05 タンパク質の半減期を増加させる方法
CN201880042102.6A CN110785429A (zh) 2017-05-05 2018-05-05 增加蛋白质半衰期的方法
EP18794624.9A EP3628681A4 (en) 2017-05-05 2018-05-05 METHODS TO EXTEND THE HALF-LIFE OF PROTEIN
JP2022138031A JP2022169770A (ja) 2017-05-05 2022-08-31 タンパク質の半減期を増加させる方法
JP2022138032A JP2022169771A (ja) 2017-05-05 2022-08-31 タンパク質の半減期を増加させる方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/KR2017/004730 WO2018203582A1 (ko) 2017-05-05 2017-05-05 단백질 반감기를 증가시키는 방법
KRPCT/KR2017/004730 2017-05-05

Publications (2)

Publication Number Publication Date
WO2018203737A2 WO2018203737A2 (ko) 2018-11-08
WO2018203737A3 true WO2018203737A3 (ko) 2019-04-25

Family

ID=64016150

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2017/004730 WO2018203582A1 (ko) 2017-05-05 2017-05-05 단백질 반감기를 증가시키는 방법
PCT/KR2018/005239 WO2018203737A2 (ko) 2017-05-05 2018-05-05 단백질 반감기를 증가시키는 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/004730 WO2018203582A1 (ko) 2017-05-05 2017-05-05 단백질 반감기를 증가시키는 방법

Country Status (5)

Country Link
US (1) US20200270301A1 (ko)
EP (1) EP3628681A4 (ko)
JP (3) JP2020518270A (ko)
CN (1) CN110785429A (ko)
WO (2) WO2018203582A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024019553A1 (ko) * 2022-07-19 2024-01-25 주식회사 유비프로틴 보툴리눔 독소 a형 경쇄 단백질의 반감기를 증가시키는 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300187A1 (en) * 2007-06-01 2008-12-04 Guy Sauvageau Mutated hoxb4 proteins with improved stability, and methods of use thereof
WO2009155464A2 (en) * 2008-06-18 2009-12-23 Life Technologies Corporation Mutated and chemically modified thermally stable dna polymerases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127652A1 (en) * 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US20030220250A1 (en) * 2002-02-14 2003-11-27 Ellis Lee M. Angiopoietin-1 in the treatment of disease
US20060153800A1 (en) * 2004-12-14 2006-07-13 Roland Buelow DNA immunization with recombinase/transposase
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US8247531B2 (en) * 2006-03-20 2012-08-21 Cochran Jennifer R Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
KR101519118B1 (ko) * 2013-07-23 2015-05-12 (주)피앤피바이오팜 고안정성 상피세포 성장인자 변이체
US20170232069A1 (en) * 2014-08-07 2017-08-17 Reponex Pharmaceuticals Aps Compositions for the treatment of peritonitis
CN114835793A (zh) * 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300187A1 (en) * 2007-06-01 2008-12-04 Guy Sauvageau Mutated hoxb4 proteins with improved stability, and methods of use thereof
WO2009155464A2 (en) * 2008-06-18 2009-12-23 Life Technologies Corporation Mutated and chemically modified thermally stable dna polymerases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATONNET, SABRINA ET AL.: "Critical Role for Lysine 133 in the Nuclear Ubiquitin-mediated Degradation of MyoD", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 7, 2004, pages 5413 - 5420, XP055383641, DOI: doi:10.1074/jbc.M310315200 *
RADIVOJAC, PREDRAG ET AL.: "Identification, Analysi s, and Prediction of Protein Ubiquitination Sites", PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 78, no. 2, 2010, pages 365 - 380, XP055559903, DOI: doi:10.1002/prot.22555 *
SOKALINGAM, SRIRAM ET AL.: "A Study on the Effect of Surface Lysine to Arginine Mutagenesis on Protein Stability and Structure Using Green Fluorescent Protein", PLOS ONE, vol. 7, no. 7, 2012, pages 1 - 12, XP055215573, DOI: doi:10.1371/journal.pone.0040410 *

Also Published As

Publication number Publication date
WO2018203737A2 (ko) 2018-11-08
JP2022169770A (ja) 2022-11-09
JP2022169771A (ja) 2022-11-09
CN110785429A (zh) 2020-02-11
WO2018203582A1 (ko) 2018-11-08
JP2020518270A (ja) 2020-06-25
EP3628681A2 (en) 2020-04-01
US20200270301A1 (en) 2020-08-27
EP3628681A4 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
PH12019501812A1 (en) Compositions and methods for the treatment of hemoglobinopathies
MX2021010559A (es) Polipéptidos efectores de crispr-cas y métodos de uso de estos.
PH12018501355A1 (en) Rsv f protein mutants
WO2020084305A9 (en) Bicyclic peptide ligands and uses thereof
AU2016316202A8 (en) Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
EP3936141A3 (en) Anti-senescence compounds and uses thereof
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MX2021008592A (es) Composiciones de trem y usos de las mismas.
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
EP4269596A3 (en) Engineered meganucleases specific for recognition sequences in the pcsk9 gene
MX2023014077A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
MX2022011077A (es) Variantes de transglutaminasa.
WO2018132821A3 (en) Elastomeric proteins
WO2018183692A8 (en) VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
WO2018203737A3 (ko) 단백질 반감기를 증가시키는 방법
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
GB2568440A (en) Modified factor H binding protein
MX2021014220A (es) Composiciones para el tratamiento de la perdida del cabello.
MX2021012152A (es) Metodos para el tratamiento de beta-talasemia.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18794624

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019560669

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018794624

Country of ref document: EP

Effective date: 20191205

ENP Entry into the national phase

Ref document number: 2018794624

Country of ref document: EP

Effective date: 20191205